Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Terns Pharmaceuticals, Inc. (TERN) had Return on Tangible Equity of -8.67% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-24.64M |
|
-- |
|
-- |
|
$27.72M |
|
$-27.72M |
|
$3.13M |
|
$-24.59M |
|
$-24.59M |
|
$-24.64M |
|
$-24.64M |
|
$-24.64M |
|
$-24.64M |
|
$-27.72M |
|
$-27.47M |
|
91.70M |
|
91.70M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$300.30M |
|
$0.06M |
|
$1.36M |
|
$301.65M |
|
$15.39M |
|
-- |
|
$2.20M |
|
$17.59M |
|
$284.07M |
|
$284.07M |
|
$284.07M |
|
87.51M |
|
| Cash Flow Statement Financials | |
$-63.09M |
|
$51.96M |
|
$0.39M |
|
$161.44M |
|
$150.70M |
|
$-10.74M |
|
$10.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-63.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.67% |
|
|
Return on Tangible Equity |
-8.67% |
-8.17% |
|
-8.67% |
|
$3.25 |
|
$-0.69 |
|
$-0.69 |
|